strong>Dermira Inc., of Menlo Park, Calif., reported positive phase IIb results for DRM04, its topical anticholinergic product, in patients with axillary hyperhidrosis, or excessive underarm sweating. The company conducted an initial phase IIb study (DRM04-HH01) of a topical formulation of an anticholinergic reference agent approved for systemic administration in other indications.